It's on the cancer front, however, where BPAX is underestimated. Treatments for pancreatic cancer, leukemia, myeloma, breast cancer, and prostate cancer are all in late-stage trials, while therapies for colorectal cancer and melanoma are in early clinical testing phases. It's a big deal because the worldwide cancer market is worth $48 billion.
While that's encouraging, what may be even more encouraging on the cancer front are the groups backing BioSante Pharmaceuticals. These cancer vaccines studies are conducted primarily at Johns Hopkins Cancer Center and are sponsored (funded) by The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and the National Cancer Institute... not exactly organizations that waste time and money one mere curiosities.
BPAX is still speculative to be sure. All biotechs are though. Let's put it like this - with or without LibiGel's disappointing results, investors have paid a lot more for shares of much riskier names. The big plunge wasn't a pipeline problem, but a perception problem. Perceptions can change pretty quickly though
As this is pretty difficult matter to understand for non-natives (like me :) ), perhaps a short explaination is possible? Or what effect can we expect this to have?
Any chance this gets halted due to "failure do deliver" on shorts? Looks like it's been on the list for 3 days. What does the SEC typically do about the likely hood of naked shorts?
News 
Market Data 
Discover 
